Clik here to view.
Cynapsus reports positive study data for APL-130277
Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) has released positive data from its recently completed CTH-104 healthy volunteer pilot study of a single, 25-milligram sublingual strip (APL-130277) dose...
View ArticleClik here to view.
Cynapsus sees no irritation in APL-130277 animal test
Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) says there was no irritation observed when testing its APL-130277 sublingual apomorphine formulation in a buccal mucosal irritation model in hamsters,...
View ArticleClik here to view.
Three BT-featured CEOs sweep EY award finalist selections
All three finalists for the EY 2014 Ontario Entrepreneur of the Year award in the health sciences category have been featured in the past on BioTuesdays.com. They are Anthony Giovinazzo of Cynapsus...
View ArticleClik here to view.
Cynapsus gets additional grant from MJFF
Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) has been awarded a new grant of $500,000 from the Michael J. Fox Foundation (MJFF) for Parkinson’s research to support clinical studies to develop...
View ArticleClik here to view.
Cynapsus to start Phase 2 trial of APL-130277
Following communication from the FDA, Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) announced that it will begin Phase 2 clinical studies for APL-130277 immediately. The CTH-105 study will be...
View ArticleClik here to view.
Cynapsus appoints Ernst & Young as auditor
The board of Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) has appointed Ernst & Young as auditor for the company, effective immediately, replacing McGovern, Hurley, Cunningham, which resigned at...
View ArticleClik here to view.
Noble ups Cynapsus price target to $2
Noble Financial Capital Markets has raised its price target for “buy-rated” Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) to $2 from $1.60. The stock finished at 59 cents on Friday. Analyst Nathan...
View ArticleClik here to view.
Cynapsus names Dr. Thierry Bilbault as CSO, EVP
Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) has appointed Dr. Thierry Bilbault, as CSO and EVP of chemistry, manufacturing and controls (CMC). In this role, Dr. Bilbault will lead the strategic CMC...
View ArticleClik here to view.
Cynapsus’ APL-130277 one of “Top Ten Neurology Projects to Watch”
Cynapsus Therapeutics’ (OTCQX:CYNAF; TSX-V:CTH) APL-130277 drug candidate for Parkinson’s disease has been recognized as one of the “Top Ten Neurology Projects to Watch” by a joint selection committee....
View ArticleClik here to view.
Cynapsus posts positive top-line PD results
Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) has released positive top-line results from its CTH-105 Phase 2 clinical trial of APL-130277 for the management of OFF motor symptoms of Parkinson’s...
View Article
